<DOC>
	<DOCNO>NCT01863693</DOCNO>
	<brief_summary>This multicenter , prospective , observational study evaluate safety efficacy Avastin ( bevacizumab ) combination chemotherapy first-line treatment patient advance epithelial ovarian , fallopian tube primary peritoneal cancer routine clinical practice . Eligible patient follow approximately 15 month .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Combination With Chemotherapy First-Line Treatment Patients With Advanced Ovarian Cancer ( OSCAR 1 )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Advanced ( FIGO stag IIIB , IIIC IV ) epithelial ovarian , fallopian tube primary peritoneal cancer previously treat chemotherapy Initiating Avastin combination chemotherapy Contraindications , warning precaution use specify Avastin Summary Product Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>